Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

STRO

+ Watchlist+ Portfolio

Sutro Biopharma, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$8.92
52-Week Range
$7.15 – $43.85
Market Cap
$141.11M
P/E (TTM)
—
EPS (TTM)
-12.42
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-37.18%
Gross Margin
-184.63%
Operating Margin
-254.72%
Profit Margin
0.00%
Current Ratio
2.94
Debt/Equity
—
Total Debt
$9.70M
Free Cash Flow
$-105.75M
Revenue Growth
-6.10%
Earnings Growth
—
Enterprise Value
$8.63M

Market Snapshot

About

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. The company uses its proprietary cell-free protein synthesis platform to create antibody drug conjugates (ADCs) and other targeted oncology treatments. Sutro is advancing multiple product candidates through clinical trials for various cancer types.